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ABSTRACT 
 
BENEFITS OF PROBIOTICS CONSUMPTION IN ADULTS WITH ALLERGIC RHINITIS: 
A META-ANALYSIS 
 
by 
Bochuan Xie 
 
Background: About 1 in every 6 Americans suffer from seasonal allergies, aka allergic rhinitis 
(AR), every year. Typical symptoms of AR include sneezing, stuffy nose and watery eyes. 
Currently, two types of medications, anti-histamines and corticosteroids, are widely used for 
relieving AR symptoms; however, in addition to the concern about drug resistance after their 
long-term use, they also cause side effects such as dry mouth and dizziness. 
Introduction: AR results from an abnormally heightened immune response triggered by 
unharmful substances in the environment. Therefore, a therapy capable of regulating the overall 
immune function of the body should alleviate the discomfort caused by AR. The intestine is the 
largest immune organ of the body. And consumption of probiotics can induce positive changes in 
the composition of the microbiota that reside in the intestine within a short period of time. As a 
result, several trials have been conducted to investigate the therapeutic effects of probiotics on 
AR. However, because of the generally small sample size of these studies, it is difficult to reach 
a definite conclusion. Therefore, we performed a meta-analysis to assess if probiotics 
consumption leads to improvement of AR symptoms. 
Method: Key words of “probiotics” and “seasonal allergy” were used to search PubMed, 
Cochrane and CINAHL to identify randomized controlled trials for the meta-analysis. Out of the 
69 initially identified papers, 9 were eventually included in the analysis. Studies excluded were 
either duplicates, reported un-relevant outcomes, or provided insufficient data for further 
analysis. The meta-analysis was conducted through CMA 2.0, commercial comprehensive meta-
analysis software. Standardized mean difference was calculated for subjective symptoms scores 
and serum biomarker levels for each study as the effect size, and the random effects model was 
applied to calculate the overall effect. 
Results:  
        
As shown in the Forest plot above, the Hedges’ g value for overall symptom score was 0.451 
with a p value of 0.02, indicating that probiotics consumption induced a moderate improvement 
in symptoms, and the improvement is statistically significant. On the other hand, the Hedges’ g 
value for blood biomarkers level was -0.15 with a p value of 0.127, meaning probiotics 
performed worse than placebo at decreasing the inflammation at cellular or molecular level, as 
measured by serum biomarkers, but this inferior effect was not statistically significant. 
Conclusion: The use of probiotics is beneficial at relieving allergic symptoms for AR patients, 
but contradictory findings were discovered when it comes to the measurement of serum 
biomarkers levels. Future studies are needed to identify reliable biomarkers for AR, and studies 
with similar design but larger sample size would be helpful to further investigate the 
effectiveness of probiotics in the management of AR. 
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 1 
Chapter I 
Benefits of probiotics consumption in adults with allergic rhinitis: A Meta-
Analysis 
Introduction 
The layman’s term of allergic rhinitis (AR) is seasonal allergies, which describes the state 
of having various nasal and ocular symptoms. These symptoms occur as a result of the body’s 
abnormally heightened immunological response to inhaled substances from the environment, 
such as tree or grass pollen, dandruff of cats or dogs, and dust mites. In addition to causing the 
physiological symptoms that are familiar to most people, e.g. itching, sneezing, runny nose, 
stuffy nose, watery eyes and headaches, AR is closely associated with significant emotional 
stress which negatively affects every aspect of a person’s daily life, including school, work, 
exercise, as well as social life
1,2
. Based on a 2012 report, 10% to 20% of people living in 
industrialized countries suffer from AR every year
2
. In the U.S., the prevalence of AR is 
estimated to be 16%, translating to 40 million people
3. What’s worse is that, when comparing 
studies spanning the past decades, the prevalence of AR has been increasing globally
2
. 
In people who have AR, the uncomfortable and sometimes miserable symptoms arise 
because protective physiological functions are out of control. Under normal conditions, the nasal 
cavity adjusts inhaled air to a comfortable temperature and level of humidity before it reaches the 
lung. Such important functions are achieved thanks to the densely packed capillary network in 
the nose, which establishes a highly efficient interface for heat exchange, and the seromucous
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glands located in the cavity that constantly secret mucus. Additionally, the mucus traps large 
airborne particles, such as dust and pathogens, thus functioning as the first line of defense. 
However, when these homeostatic and defensive functions are impaired, which is the 
case in AR, characteristic allergic symptoms appear. Stuffy nose and subsequent headaches 
result from the blockage of the nasal airway caused by the abnormal engorgement of the blood 
vessels; runny nose is the direct effect of excessive mucus secretion
4
. 
The development of allergic responses in the nasal cavity consists of three stages: 
allergen sensitization, acute response, and chronic allergic inflammation
1,4
. During the first stage, 
antigen presenting cells (APCs) engulf allergens upon the encounter. The allergens are then 
broken down into peptide segments, which are later presented to naïve T cells (Th0 cells) once 
the APCs migrate into the lymph nodes. This interaction between APCs and Th0 cells leads to 
the multiplication and differentiation of Th0 cells, giving rise to either Th1 or Th2 cells. Th1 
cells have been studied intensively because of their immune regulatory function. Th2 cells have 
the ability to bind with B cells, triggering their transformation into plasma cells that can produce 
and secret IgE into blood circulation. The high-affinity receptors on the cell membrane of mast 
cells and basophils enable their capturing of the circulating IgEs. This also signifies the 
completion of the stage of allergen sensitization. Whether the Th0 cells develop into Th1 cells or 
Th2 cells depends on the signals they receive from both the APCs and the immediate 
environment. Dendritic cells (DCs), the most thoroughly studied APCs by far, are found to play a 
crucial role in this transformational process. Once again, the precursor DCs could be activated to 
become either DC-1 cells or DC-2 cells, depending on the chemical signals in the vicinity. When 
Th0 cells interact with DC-1 cells in an IL-12 rich environment, Th1 cells are generated. In 
contrast, if the interaction taking place is between Th0 cells and DC-2 cells in an environment 
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with high level of IL-4, Th2 cells are formed. High levels of Th2 cell count have been reported to 
strongly relate to seasonal allergies. The second stage is acute response that initiates within 
minutes after the inhalation of a previously exposed allergen. The first step is the recognition of 
the allergens by the mast cells and basophils through the allergen-antibody (IgE in this case) 
interaction. The subsequent binding of multiple mast cells and basophils with each single 
allergen molecule leads to the cross linking between IgEs, thus opening the calcium channel of 
these cells. As a result, these cells are activated and begin to release the mediators that are 
packaged in the intracellular granules. Mediators involved at this step include histamine, 
proteases and leukotrienes. After reaching the intracellular space, each mediator binds to its 
specific receptors, which are located either on blood vessels or glands, to trigger the onset of 
various symptoms. For example, binding of histamine with H1 receptors on the sensory nerve 
endings quickly leads to sneezing, itching, and excessive mucus secretion. Binding of histamine 
with either H1 or H2 receptors on the mucosal blood vessels causes the vessels to swell, 
eventually leading to congestion. Nasal blockage and excessive discharge may also result from 
the binding between leukotriene and CysLT1 or CysLT2 receptors on blood vessels and 
secretary glands in the nasal cavity. Meanwhile, these mediators attract more mast cells and 
basophils, causing the release of more mediators. This self-driving vicious cycle causes the 
symptoms to become more and more severe. Chronic inflammation, the third stage of the 
development of allergic responses, is characterized by the hyper-responsiveness of the nose to 
allergens and non-allergic stimuli. At this stage, more and different types of inflammatory cells 
are drawn to the sites of inflammation and become activated. These cells include, but are not 
limited to, basophils, eosinophils, neutrophils, monocytes, and various T cells. The chemokines 
and cytokines released not only attract more inflammatory cells, but also sustain the existing 
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inflammation, resulting in the gradual damage of the nasal epithelial cells, and consequently 
increase the permeability of the nasal epithelium. Therefore, the allergens can more easily 
penetrate the epithelium barrier, encounter IgE bearing cells, and trigger the following 
inflammatory reactions. Moreover, the prolonged inflammation makes the nerve endings, 
mucosal blood vessels, and seromucous glands more sensitive, accounting for their heightened 
response to allergens and stimuli that are not allergen in nature, for instance, cold air and 
smoke
1,4
. 
The current treatment for AR includes antihistamine medication, nasal corticosteroid 
sprays, nasal antihistamine sprays, and subcutaneous injection of allergens. While being able to 
reduce the discomfort level of AR effectively, each therapy has its own side effects, with dry 
mouth and drowsiness being the most common. Additionally, AR brings a heavy financial 
burden. In 2002, it was reported that every AR patient spent on average of about $300 on 
physician office visits and medication. There is also indirect financial loss associated with 
absence from work
5
. Therefore, it is important to discover new treatments that decrease or 
eliminate side effects, and are less expensive. The use of probiotics has shown such promise. 
Etymologically, probiotics means “for life”6. The concept of probiotics was first 
proposed in 1907 by Eli Metchnikoff, who won the Nobel Prize for his pioneering work in the 
field of intestinal microecology. He stated that useful microbes and harmful microbes coexisted 
in the human intestinal flora, and that it was probable to alter the flora’s composition7. In 1965, 
Lilly and Still coined the term probiotics, defining substances produced by micro-organisms that 
had the capability to promote the growth of other micro-organisms
8
. Currently, a widely 
accepted definition of probiotics is the one from WHO: “live organisms when administered in 
adequate amounts confer a health benefit on the host”7. The rationale of using probiotics in 
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treating AR lies in the discoveries that 1) the GI tract, the largest immune organ, plays a 
significant role in the regulation of immune function; 2) there are considerable differences in the 
composition of the intestinal flora between AR patients and healthy individuals; and 3) 
probiotics are able to change the composition of intestinal flora very quickly
9
. 
The intestinal epithelium is the largest immune organ of the body with multiple layers 
comprising its defensive system
6
. The first layer is a physical barrier between the environment 
and the body. This barrier is formed by the tight junctions and adhesion junctions along the 
lateral membranes of the epithelial cells. With fibrils made of complex lipoproteins, permeability 
of these junctions can be regulated. For instance, pro-inflammatory cytokines like TNF-α can 
induce the internalization of these junctions, thus disrupting the barrier. The second layer is an 
antibacterial barrier established by epithelial cells and phagocytes that reside in the intestine due 
to their ability to produce antimicrobial peptides. These peptides identify microbes then insert 
themselves into their cell membranes, leading to the rupture and death of the microbes. 
Additionally, these peptides can interfere with the metabolic and biosynthetic pathways of the 
pathogens. The third line of defense is the intestinal flora, which is composed of over 400 species 
with a cell count of approximately 10
14
. Healthy intestine flora produce organic acids and 
hydrogen sulfide, forming a hostile environment to reduce the colonization of pathogens. 
Moreover, the flora constantly and actively interact with the epithelial cells to regulate their 
expression of antimicrobial peptides
6
. 
The barrier functions of the intestinal epithelium are reinforced by the body’s immune 
system. Gut-associated lymphoid tissue (GALT) is the largest lymphoid tissue of the body. It is 
located throughout the intestine and is composed of Peyer’s patches, mesenteric lymph nodes, 
and scattered lymphocytes. Cells in GALT include dendritic cells, macrophages, B cells and T 
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cells. These immune cells possess the capability to differentiate between self and pathogens 
primarily through the detection of microbe-associated molecular patterns (MAMPs) on 
pathogens, such as Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-
like receptors (NLRs). Once pathogens are recognized, the synthesis and secretion of pro-
inflammatory cytokines, adhesion molecules, and antimicrobial peptides in these cells and 
adjacent cells are triggered, thus activating the immune defense system
6
. 
It is hypothesized that through binding with TLRs, especially TLR-2 and TLR-9, 
probiotics may initiate specific signal pathways to exert immune regulatory functions
10
. 
Probiotics might help strengthen the junctions between epithelial cells so that the physical barrier 
is less permeable to the contents such as food particles and pathogens, in the intestinal lumen. As 
a result, the body is less likely to mount an abnormal immunological response
10
. Additionally, 
damaged epithelium heals faster in the presence of probiotics
10
. Probiotics have also been found 
to decrease the synthesis of pro-inflammatory cytokines such as IL-4, while increasing the level 
of anti-inflammatory cytokines like IL-10 and IFN-γ. Probiotics are capable of suppressing the 
IgE production by B cells, which might slow down the progression of AR from the onset
10
. 
Lastly, probiotics have been reported to divert the body’s immune response to a tolerant mode. 
In two in vitro studies, precursor DCs were primed to transform to DC-1 cells when cultivated 
with probiotics
1,4
. Since DC-1 cells direct Th0 cells to develop into Th-1 cells, the cytokine 
profile would be anti-inflammatory
1,4
. 
In contrast to traditional understanding, the dysbiosis theory, a relatively new theory, 
proposes that many diseases including autoimmune diseases, allergies, and inflammatory bowel 
diseases result from the imbalance of microbes in the intestine flora
9
. This theory is supported by 
the finding that the cell counts of Lactobacillus spp. and Bifidobacterium adolescentis of AR 
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patients are much lower than the ones of healthy individuals. The composition of intestine flora 
is greatly influenced by diet, health status, and environmental factors. The encouraging news is 
that microbiota composition can be altered within 24 hours after a positive dietary change
9
. All 
these findings strongly support the practice of dietary intervention in AR patients. It is expected 
that healthy balanced intestine flora established by direct administration of probiotics, would 
help the body react to inhaling allergens more mildly, thus limiting the damage caused by 
inflammation. The objective of this study is to investigate if oral probiotics consumption reduces 
the allergic symptoms in users compared to non-users. 
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Chapter II 
Review of literature 
Two most commonly used bacterial genera as probiotics are Lactobacillus and 
Bifidobacterium, both of which are Gram-positive, produce lactic acid, and make up a large 
fraction of the normal intestinal flora in humans
11
. Members of Lactobacillus being investigated 
for potential probiotic functions include Lactobacillus acidophilus, Lactobacillus casei, 
Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus spp., Lactobacillus reuteri, 
Lactobacillus delbrueckii,and Lactobacillus fermentum. Members of Bifidobacterium being 
studied consist of Bifidobacterium spp., Bifidobacterium longum, Bifidobacterium bifidum, 
Bifidobacterium breve, Bifidobacterium lactis,and Bifidobacterium infantis
11
. A handful of 
studies also explored the prospectively probiotics roles of other microbes; e.g., yeasts and some 
E. coli strains that are not pathogenic
11
. Probiotics come from two major sources: natural source 
and nutrition supplement. The natural source refers to different kinds of fermented foods, such as 
yogurt, kefir, miso, tempeh, and sauerkraut. Probiotics supplements are packaged in various 
forms: powder, capsule, and even in herbal tea. They have evolved into a multi-billion-dollar 
market globally with a sale of $1.3 billion in 2010 and is predicted to reach $2.07 billion by 
2015
12
. The use of probiotics has been evaluated in several diseases characterized by abnormal 
immune response. Isolauri et al. reported that the oral administration of Bifidobacterium or 
Lactobacillus strains helped relieve the symptoms of food allergy
13
. Anaphylactic symptoms as a 
result of food allergy were reduced when the probiotics mixture VSL#3 (highly potent probiotic 
mixture comprising of 8 strains of live bacteria with up to 900 billion counts in one packet
14
) and
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Lactobacillus casei strain Shirota were consumed
15
. The use of probiotics have been shown to 
prevent the onset of eczema
16–18
. Probiotics used in these studies include Lactobacillus
 rhamnosus, Lactobacillus GG, Lactobacillus reuteri and Bifidobacterium lactis. The 
prevalence of eczema in the control group was two times higher than that of the intervention 
group
16,17
. Lactobacillus GG, Lactobacillus plantarum, and Bifidobacterium-12 exerted 
protective effects in animal models with asthma. The probiotics reduced the allergic 
inflammation of the animals’ airways19,20, and suppressed the allergen-induced degranulation of 
basophils. Similar to the above diseases, AR results from abnormal allergic response. To date 
researchers around the globe have conducted many studies to investigate the effects of probiotics 
consumption on patients suffering from AR. However, these studies reported inconsistent results. 
For example, a couple studies reported that the use of probiotics reduced the inflammation in the 
patients measured by biomarkers including IgE, eosinophils, and IFN-γ, while some studies 
reported the opposite
21–29
. Several studies showed that probiotics improved the subjective 
symptoms such as nose symptom and eye symptom of the patients assessed by subjective 
questionnaires, while some studies concluded that probiotics consumption did not bring about 
more benefits than placebo
21–29
. These details are presented in the following result section. 
Furthermore, most of these studies had comparatively small sample size, which limits their 
capability to draw convincing conclusions. Consequently, the objective of this study is to assess 
the effectiveness of probiotics consumption in treating AR through meta-analysis, and make 
suggestions for future studies. 
 10 
Chapter III 
Methods 
Inclusion criteria 
 A study needed to fulfill the following requirements to be included in this analysis: 
double blinded, placebo-controlled trial; the participants of the studies were adults (>18 years 
old); the participants had been clinically diagnosed with AR; and reported outcomes included 
either subjective symptom scores and/or blood biomarker levels of IgE, eosinophils, and IFN-γ.  
Search strategy 
 Three main databases in the field of life science (PubMed, Cochrane and CINAHL), were 
searched to identify the studies to be included in the meta-analysis. The search was conducted on 
February 12, 2013, as a result, it is guaranteed that even the most recently published studies are 
included. Searching PubMed using MeSH words “Rhinitis, Allergic, Seasonal” and “Probiotics” 
generated 27 hits. Searching Cochrane with “allergic rhinitis” and “probiotics” as “ALL TEXT” 
found 37 papers. Lastly, using “CINAHL heading”, equivalent to MeSH in PubMed, the search 
identified 5 articles. 
11 
 
 
     
 
 The process of selecting the studies to be included in the meta-analysis is shown in 
Figure 1. Out of the total 69 papers, 17 papers were excluded as a result of duplication. 
Seventeen more papers were excluded based on their title, primarily because the study used 
animal models, or the participants were not adults. Another reason for the exclusion of some 
studies based on title is that they were published in a foreign language that could not be easily 
understood. Sixteen papers were further excluded based on the abstract since they did not meet 
the inclusion criteria; e.g., the experiment was conducted on children or infants, or the study 
reported outcomes other than subjective symptoms or blood biomarker levels like fecal microbe 
composition. Lastly, after reading through the whole text, 10 additional papers were excluded 
due to the fact that when reporting the outcomes of interest, they did not present data in forms 
that could be used in the meta-analysis. For example, some studies presented the results as 
Fig. 1 Flow chart of paper selection 
12 
 
 
figures, but did not report the actual values, such as mean and SD; other studies showed the 
results as ratios of post-intervention over pre-intervention measurement; and some studies simply 
made a statement of not finding significant difference between the intervention group and the 
placebo group, while giving no detailed values.   
 The general information of the 9 selected studies
21–29
, such as the year of the publication, 
the duration of the intervention, the strain of probiotics that is used, the number of participants, 
and  the synopsis of the results, is summarized in Appendix 1.   
Data extraction 
 The following information is extracted from the selected studies for the analysis: first 
author and publication year, duration of the study, each outcome with respective pre- and post- 
measurement of means and standard deviations for control and intervention group, sample sizes, 
the dosage of the intervention, and the form of the intervention. 
Statistical analysis 
 Comprehensive Meta-Analysis Version 2.0, commercial meta-analysis software, was 
used to perform the statistical analysis. Because different methods were used to measure 
outcomes in the selected studies, standardized mean difference was chosen as the effect size of 
individual studies. Randomized effects model was used to calculate the overall effect size, 
because of the existence of several differences among the studies: probiotic strains, varied 
duration of the intervention, and inherent genetic difference of the participants. In addition, due 
to the generally small sample sizes, Hedges’ g, standardized mean difference after correction, 
was used for further analysis and plotting. Corresponding 95% CIs were calculated. Lastly, meta-
analyses of the comparison between the placebo and probiotic groups were conducted on the 
following outcomes: allergen-specific IgE, eosinophil count, IFN-γ, Th1/Th2, eye symptom 
13 
 
 
score, nose symptom score, and overall symptom score. In studies that measured similar 
outcomes, the values of measured outcomes were combined to determine the effect size. For 
example, sneezing, runny nose, stuffy nose, and itchy nose were grouped together as nose 
symptoms. The study by Koyama in which IgE against three different types of pollens were 
measured, their values were combined during the analysis due to the similar nature of the three 
measures. 
  Two subgroup analyses were then performed. One assessed if there was a difference in 
the effects on symptoms vs. blood biomarker between placebo and probiotic groups. The other 
one assessed if there were different effects between the uses of dairy vs. non-dairy as the 
treatment.  
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Chapter IV 
Results 
IgE 
 Seven selected studies
21–26,29
 reported IgE as an outcome, and none of them presented a 
statistically significant difference between the placebo and the probiotics group. The overall 
effect barely favors the placebo group, with the overall effect size of -0.085 (Fig. 2), but is not 
statistically significant. (p=0.468, Appendix 2). 
 
 
Fig. 2 Meta-analysis based on the outcome of IgE 
15 
 
 
Eosinophil 
 Five selected studies
24–27,29
 reported either eosinophil count or eosinophil % as an 
outcome, and only one of the studies
25
 found a statistically significant difference between the 
placebo and the probiotics group, with an effect size of -0.801, and a p value of 0.016 (Fig. 3). 
The overall effect slightly favors the placebo group, with the overall effect size of -0.145 (Fig. 
3), but  is not statistically significant. (p=0.371, Appendix 3). 
 
 
 
 
 
 
Fig. 3 Meta-analysis based on the outcome of eosinophil 
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IFN-γ  
 Three selected studies
21,24,26
 reported IFN-γ as an outcome with one24 presenting a 
statistically significant difference between the placebo and the probiotics group, with an effect 
size of -1.037, and a p value of 0.006 (Fig. 4). The overall effect moderately favors the placebo 
group, with the overall effect size of -0.529 (Fig. 4), which is almost statistically significant 
(p=0.067, Appendix 4). 
 
 
 
 
 
 
Fig. 4 Meta-analysis based on the outcome of IFN-γ 
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Th1/Th2 
 Three selected studies
22,23,25
 reported Th1/Th2 as an outcome with one
25
 presenting a 
statistically significant difference between the placebo and the probiotics group, with an effect 
size of -1.865, and a p value of 0.000 (Fig. 5). The overall effect moderately favors the placebo 
group, with the overall effect size of -0.535 (Fig. 5), but is not statistically significant (p=0.391, 
Appendix 5). 
 
 
 
 
 
 
Fig. 5 Meta-analysis based on the outcome of Th1/Th2 
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Eye symptoms 
 Three selected studies
23,24,26
 reported eye-related symptom scores as outcomes, with one
24
 
presenting a statistically significant difference between the placebo and the probiotics group, 
with an effect size of 0.594, and a p value of 0.05 (Fig. 6). The overall effect moderately favors 
the probiotic group, with the overall effect size of 0.35 (Fig. 6), and is statistically significant 
(p=0.013, Appendix 6). 
 
 
 
 
 
Fig. 6 Meta-analysis based on the outcome of subjective eye symptoms score 
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Nose symptoms 
 The same three studies
23,24,26
 reported nose-related symptom scores as outcomes, with 
one
24
 presenting a statistically significant difference between the placebo and the probiotic 
group, with an effect size of 0.781, and a p value of 0.011 (Fig. 7). The overall effect moderately 
favors the probiotic group, with the overall effect size of 0.349 (Fig. 7), and is barely statistically 
significant (p=0.047, Appendix 7). 
 
 
 
 
 
 
Fig. 7 Meta-analysis based on the outcome of subjective nose symptoms score 
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Overall subjective symptom scores 
 Four selected studies
23,24,26,28
 reported subjective symptom scores as outcomes with 
two
24,28
 presenting a statistically significant difference between the placebo and the probiotics 
group, with an effect sizes of 0.730 and 1.315, and a p values of 0.017 and 0.023, respectively 
(Fig. 8). The overall effect moderately favors the probiotic group, with the overall effect size of 
0.451 (Fig. 8), and it is statistically significant (p=0.020, Appendix 8). 
 
 
 
 
 
Fig. 8 Meta-analysis based on the outcome of overall subjective symptoms score 
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Blood biomarkers vs. symptom scores 
 Subgroup analysis based on blood biomarkers vs. symptom scores reveals that the 
placebo appeared to have induced better outcomes with regard to the measurement of blood 
biomarkers, but this seemly superior effect is not statistically significant, with an overall effect 
size of -0.150, and a p value of 0.127 (Fig. 9). Judging based on the subjective symptom scores, 
probiotics show a statistically significantly better outcome than the placebo, with an overall 
effect size of 0.451, and a p value of 0.02 (Fig. 9). And the difference between the two subgroup 
analysis is statistically significant (p=0.006, Appendix 9). 
 
 
 
Fig. 9 Subgroup analysis based on the outcome of blood biomarkers measurement 
vs. subjective symptoms score 
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Dairy vs. Non-dairy 
 Subgroup analysis based on the type of the intervention, dairy form vs. non-dairy form of 
the probiotics, reveals that intervention with non-dairy form seems to have produced better 
overall outcomes. The outcomes were calculated combining both blood biomarkers measurement 
and subjective symptoms score. The superior effect of non-dairy intervention is not statistically 
significant, with an overall effect size of 0.184, and p value of 0.200 (Fig. 10). Intervention with 
dairy form actually had a worse performance than the placebo group, with an overall effect size 
of -0.030, and a p value of 0.912 (Fig. 10). The difference between the two subgroup analysis is 
not statistically significant (p=0.2, Appendix 10). 
 
 
Fig. 10 Subgroup analysis based on the type of the intervention: dairy form vs. 
non-dairy form 
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Chapter V 
Discussion and Conclusions 
 The results of the meta-analysis in this study showed that the participants from the groups 
consuming probiotics reported an overall lower score for subjective symptoms, compared to 
those from the placebo groups, and the difference between the two groups was statistically 
significant with a p value of 0.02 (Fig. 9). In other words, probiotics consumption indeed 
effectively reduced the allergic symptoms. However, the observed improvement of the subjective 
symptoms scores did not align with the objective measurement of the concentration of the serum 
biomarkers. As a matter of fact, the results of all the objective measurements indicated an 
inferior effect of the probiotics treatment than the placebo treatment, although none reached a 
statistically significant level. Many reasons could potentially explain this contradiction. First of 
all, the researchers might not have chosen reliable serum biomarkers. Second, even if a good 
choice of biomarkers was made, the researchers might not have collected the most optimal 
sample for measurement. Lastly, there reason has been debate over the merits of subjective 
symptoms assessment, since widespread doubt exists in the life science field regarding the 
assessment of subjective symptoms through questionnaires.  
 Theoretically, every molecule involved in the allergic chain reaction could be a 
biomarker for the assessment of the AR status, but due to the varied biological attributes of these 
molecules and the technical difficulties of the measurement, only a few have been used as 
biomarkers in AR-related research studies. Even fewer of them have been evaluated for their 
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validity and reproducibility. Levels of IgE, eosinophil count, Th1/Th2 ratio, and IFN-γ 
concentration are parameters that have drawn the most attention. 
IgE 
 The majority of the included studies (7 out of 9) reported IgE level as an outcome. 
Unfortunately, most of these studies simply stated that the peripheral serum sample was collected 
for the measurement of IgE level, while providing no further details regarding how the 
measurement was taken. The remaining studies failed to mention the type of sample that was 
collected for the subsequent measurement. After being captured by mast cells and basophils 
through FcεRI receptors on their cell membrane, IgEs crosslink in the presence of specific 
allergens, causing the degranulation of the effector cell to which they bind, which is then 
followed by the progression of the allergic responses
30
. Based on the understanding of this vital 
role of IgE in the development of AR, drugs capable of interfering with the interaction between 
IgE and its effector cells have been designed to treat allergic diseases. Omalizumab, humanized 
antibody against IgE, is an example. Omalizumab reduces the symptoms of allergic asthma, and 
decreases the use of other traditional medications
31
. Therefore, IgE level possesses the attributes 
of a reliable biomarker, both in theory and in practice. However, two questions need to be 
answered regarding its use for assessing the severity of the AR. First, since IgE exists in the body 
in two forms, cell-bound and free form, it is important to find out which one is the better marker. 
Second, IgEs can be found in the blood circulation as well as in the nasal fluid discharge; 
therefore, it is equally important to know which fraction of IgE is more relevant when studying 
AR. The majority of IgEs tightly bind to the cell membrane of mast cells and basophils, due to 
this physical connection, these IgEs exist for a long period of time. On the other hand, the freely 
floating IgEs in blood circulation are not stable, having a half-life of about two days
31
. Therefore, 
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support for choosing free-form IgE over cell-bound IgE as the biomarker seems reasonable, 
because studies of AR are generally constrained by the length of the pollen season, which lasts 
two to three months. This might not leave enough time for a molecule with a long life-time to 
show a change. In contrast, measuring a molecule with a quick turn-over rate assesses the real-
time response of the body, in this case, IgE synthesis to the intervention of probiotics 
consumption. Using free-form IgEs as the biomarker has been vindicated by the finding from 
studies using flow cytometry: free IgEs in the serum sample positively correlate with the 
concentration of IgE-bearing monocytes and basophils
31
. Additionally, the technique of 
measuring free IgEs in serum sample is considerably easier than measuring IgEs bound to the 
effector cells.  
 IgE-producing cells and IgEs have been easily detected in the nasal lavage fluid that is 
collected by simple techniques such as Nasal lavage (NAL) technique. In comparison, nasal 
brushes (NAB), which obtains cells from the nasal mucosa, is more accurate at evaluating the 
cell profile
31
. Plasma cells (PCs), one form of activated B cells that secret specific IgEs, reside 
not only in the bone marrow but also in the respiratory mucosa
31
. During the pollen season, the 
majority of the IgEs that are grass-pollen specific are secreted by the PCs in the respiratory 
mucosa; and this de novo synthesis and secretion of pollen-specific IgEs take place throughout 
the whole pollen season
31
. Because of the close connection between IgEs with mast cells and 
basophils, measuring IgE levels at where symptoms occur, e.g. nose, should be more relevant 
and more accurate at indicating the severity of the inflammation.  
Eosinophils 
 Most of the included studies (7 out of 9) reported either eosinophil count or eosinophil % 
as an outcome. In six of these seven studies, eosinophils from serum samples were counted. One 
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study counted eosinophils from the nasal lavage fluid samples. None of the authors provided 
details regarding how the counting was conducted. Activated eosinophil is a key effector cell 
type that plays important role in maintaining the inflammation of the nasal mucosa, thus leading 
to a chronic inflammatory status of the nose. Therefore, eosinophil count should be a very 
informative biomarker for evaluating the severity of the nasal chronic inflammation in patients 
with AR. However, it is crucial to distinguish activated eosinophils from non-activated 
eosinophils. A major difference between the two is that only activated eosinophils synthesize and 
present BMK13 on their cell membranes
32
. Researchers have also begun using eosinophil cation 
protein (ECP) as a surrogate for activated eosinophils, because ECP is a soluble protein only 
secreted by activated eosinophils. Along with the transition from non-pollen season to pollen 
season, the level of ECP in AR patients increases dramatically. Additionally, a moderate 
correlation (r=0.53) has been reported between ECP concentration and nasal symptoms during 
the pollen season
32
. Furthermore, ECP has been measured in drug trials to evaluate the 
effectiveness of the treatment. In one study, the application of fluticasone, a widely used nasal 
corticosteroids spray, reduced the average ECP level of AR patients to one sixth of its starting 
value. Additionally, the severity of allergic symptoms assessed by subjective symptom 
questionnaires decreased by 75%
32
. Considering that measuring the concentration of a soluble 
substance generally has much lower requirement for instruments and skills than measuring the 
quantity of a certain type of cell with specific surface molecules, ECP appears to be a better 
option. 
 Both eosinophils and ECP can be easily measured from the nasal lavage fluid. Since 
eosinophils are recruited to the site of inflammation (nose in the case of AR) and function to 
maintain the inflammatory status, the measurement at the local level, compared to the 
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measurement in the blood, should be more sensitive at detecting the change of the severity of the 
allergic symptoms caused by the intervention. 
IFN-γ 
 A small number of the selected studies (3 out of 9) reported the measurement of IFN-γ 
level from serum sample as an outcome. IFN-γ is a Th-1 specific cytokine30 that is capable of 
inhibiting the transformation of Th0 to Th2 cells. Additionally, IFN-γ can suppress the 
inflammatory reactions of the effector cells, including mast cells and eosinophils
33
. Although 
many researchers conducting studies related to inflammation have measured IFN-γ level, its 
applicability as a biomarkers for studies about AR has not been established. The underlying 
reason might be the contradictory functions of IFN-γ. While possessing the ability to suppress 
the allergic reactions, IFN-γ is a strong pro-inflammatory cytokine and a vital signal for the 
activation of macrophages. Activated macrophages release highly toxic molecules, such as 
oxygen radicals and nitric oxide, causing localized tissue damage
30
. Neither high nor low levels 
of IFN-γ can indicate an improved inflammatory status of the local organ or the whole body, so 
alone it would not be a good choice as a biomarker.  
Th1/Th2 
 A small number of the selected studies (3 out of 9) reported the ratio of Th1/Th2 from 
serum sample as an outcome. One study provided no details regarding the test, and the other two 
reported counting cells using flow cytometry. Th1 cells were identified with CD4+, IFN-γ+, and 
IL4-, while Th2 cells were identified with CD4+, IFN-γ-, and IL-4+. The cytokine profile of Th2 
cells is pro-allergenic, primarily because IL-4 promotes the class switching of immunoglobulins 
in B cells, giving rise to the synthesis of allergen-specific IgE. In contrast, the cytokines 
produced by Th1 cells, including IFN-γ and IL-12, exert an inhibitory effect on the 
transformation of Th0 cells into Th2 cells. Decreased Th2 cell count induced by immunotherapy, 
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and the consequent shift of the balance from Th2 towards Th1 side, was found to be associated 
with lower subjective symptoms scores and less medication use
33
. Nevertheless, an abnormally 
skewed balance of Th1/Th2 towards the Th1 side carries its own risk of rendering individuals 
vulnerable to develop contact dermatitis as the result of macrophage activation. An example of 
contact dermatitis is the development of rash, sometimes even blisters, after touching poison 
ivy
30
. Therefore, Th1/Th2 appears to be a good biomarker for studies about AR as long as it is 
within a certain range. Th1 and Th2 cells play important roles at the early stage of the 
development of AR, and their ratio seems to set the tone of the overall inflammatory status of the 
body. Therefore, measuring the ratio is appropriate to assess potential long-term effects. 
Measuring Th1/Th2 from serum sample also supports the fundamental idea behind the use 
probiotics for AR management: the human body exists as an integrative entity, so an event taking 
place at one part of the body has influence on other parts of the body. Generally, such effects 
occur as a result of certain molecules traveling through the circulatory system. Positively altering 
the composition of the microbiota in the intestine should first lead to positive changes of immune 
response locally, then throughout the whole body, as a result improving diseases with abnormal 
immune response in nature. 
Subjective symptoms scores 
 Researchers in the field of life science generally are reluctant to use subjective perception 
as the outcome, because these measurements indeed vary significantly between individuals, and 
they cannot be objectively and repeatedly quantified. These outcomes are easily affected by 
factors other than the treatment, such as mood change, energy level, and trivial things that 
happen in everyday life. Probably due to these concerns, less than half of the selected studies that 
are included in this analysis assessed and reported the subjective symptoms scores. If a study is a 
double-blinded and placebo-controlled trial, the psychological influence due to placebo effect 
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should be ruled out; moreover, interpersonal variance and mood changes are unlikely to mask or 
even reverse the effects of the treatment as long as the sample size is big enough and the duration 
of the intervention is long enough. Furthermore, drug trials, which have the reputation of being 
rigorous, have repeatedly reported the improvement in subjective symptoms scores due to the 
drug application. The intervention with probiotics consumption is conducted on people with AR 
living in a real world, where confounding factors are difficult to control.  What really matters to 
a patient is how he/she perceives his/her quality of life. Even golden biomarkers are discovered, 
the assessment of subjective symptoms still has its advantages, because human beings exist as a 
inseparable entity of subjective body and objective soul. 
 In summary, the intervention of probiotics consumption has low risk, is cost-effective, 
and is capable of decreasing symptoms and improving life quality. Therefore, Probiotics are 
worth trying for AR patients who are open to alternative therapies. 
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Appendices 
1. Summary of included studies 
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2.  Test of  statistical significance of IgE level between probiotics groups and placebo groups 
 
3. Test of  statistical significance of eosinophil count between probiotics groups and placebo groups 
 
4. Test of  statistical significance of IFN-γ level between probiotics groups and placebo groups 
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5. Test of  statistical significance of Th1/Th2 between probiotics groups and placebo groups 
 
6. Test of  statistical significance of eye symptoms score between probiotics groups and placebo groups 
 
7. Test of  statistical significance of nose symptoms score between probiotics groups and placebo groups 
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8. Test of  statistical significance of overall objective symptoms score between probiotics groups and placebo groups 
 
9. Test of  statistical significance of subgroup analysis of blood biomarkers level vs. symptoms score 
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10. Test of  statistical significance of subgroup analysis of dairy-form intervention vs. non-dairy-form intervention 
 
 
 
